40Hz Frequency Therapy: The Science of Gamma Stimulation for Brain and Body

Your brain has a frequency. Not metaphorically. Not in some vague "raise your vibration" sense. Literally. Right now, billions of neurons in your brain are firing in rhythmic patterns, and one frequency in particular has captured the attention of neuroscientists around the world: 40 cycles per second.

This is the gamma rhythm. It is the brain's signature of focused attention, memory consolidation, and higher cognitive function. And over the past decade, a growing body of peer-reviewed research, much of it from MIT, has revealed something remarkable: when you stimulate the brain at 40Hz through sound, light, or physical vibration, measurable changes occur at the cellular level. Neurons are preserved. Toxic proteins are cleared. The brain's waste-removal plumbing activates. Cognitive function improves.

But the effects of 40Hz stimulation do not end at the brain. Vibration at this frequency has been studied for its impact on pain, muscle recovery, bone density, circulation, and motor function in conditions like Parkinson's disease. The research spans neuroscience, rehabilitation medicine, and musculoskeletal health, and it points to 40Hz as a frequency the entire body responds to in meaningful, measurable ways.

This is not fringe wellness theory. This field now includes Nature publications, exploratory and pivotal human trials, and an FDA Breakthrough Device-designated investigational device from Cognito Therapeutics.

And it has everything to do with what we build at Zenthesia.

What Are Gamma Oscillations?

Gamma oscillations are rapid neural rhythms ranging from about 25 to 100Hz, with 40Hz occupying a uniquely important position. These oscillations arise from the synchronized firing of neurons, governed by inhibitory interneurons that use GABA receptors to create a rhythmic push-pull of excitatory and inhibitory signals across neural networks.

When your brain is actively processing information, paying close attention, encoding a new memory, or integrating sensory input from multiple sources, gamma activity increases. It is the frequency of coherence, the brain's way of binding disparate pieces of information into a unified experience.

This is not abstract neuroscience. Gamma oscillations have been directly linked to memory encoding, working memory, attention, and sensory processing in dozens of peer-reviewed studies. When gamma rhythms are disrupted, as they are in Alzheimer's disease, Parkinson's disease, and other neurological conditions, cognitive function declines. The question researchers began asking was simple: what happens if we restore them?

Key Research:

• Gamma Oscillations in Alzheimer's Disease and Their Potential Therapeutic Role (Frontiers in Systems Neuroscience, 2021)
• Unleashing the Potential: 40Hz Multisensory Stimulation Therapy for Cognitive Impairment (PMC, 2025)

The Breakthrough: MIT's GENUS Research

The modern story of 40Hz therapy begins in 2016, when a team led by Dr. Li-Huei Tsai at MIT's Picower Institute for Learning and Memory published a landmark paper in Nature. They first used optogenetic stimulation to drive parvalbumin-positive interneurons at 40Hz in Alzheimer's model mice, showing that this reduced levels of amyloid-beta, one of the hallmark pathological proteins associated with Alzheimer's disease. Critically, they then extended the finding to a noninvasive approach: 40Hz flickering light delivered through the eyes produced similar reductions in amyloid levels and plaque load in multiple mouse models.

The results were striking enough that the research community took notice. Over the following years, Tsai's lab expanded the work dramatically. They showed that 40Hz stimulation delivered through light, sound, and the two combined could reduce both amyloid and tau proteins, prevent neuron death, preserve synaptic connections, and sustain memory and cognition in multiple Alzheimer's mouse models. They called the approach GENUS: Gamma Entrainment Using Sensory Stimulation.

Key Research:

• Iaccarino et al., Gamma Frequency Entrainment Attenuates Amyloid Load and Modifies Microglia (Nature, 2016)
• Park & Tsai, Innovations in Noninvasive Sensory Stimulation Treatments to Combat Alzheimer's Disease (PLOS Biology, 2025)
• Evidence That 40Hz Gamma Stimulation Promotes Brain Health Is Expanding (MIT News, 2025)

The Glymphatic Connection: How 40Hz Clears the Brain

Perhaps the most exciting mechanistic discovery came in February 2024, when Tsai's team published another paper in Nature revealing how 40Hz stimulation actually works to clear toxic proteins from the brain. The answer involves the glymphatic system, a waste-clearance network that runs parallel to the brain's blood vessels.

Here is what they found (in a mouse study): multisensory 40Hz stimulation (combined light and sound) promoted the influx of cerebrospinal fluid into brain tissue and the efflux of interstitial fluid carrying waste products out. The stimulation increased the polarization of aquaporin-4 (AQP4) water channels on astrocyte cells, which are critical gatekeepers for fluid exchange. It dilated meningeal lymphatic vessels that drain waste. It increased arterial pulsatility, essentially pumping more fluid through the system.

A separate study from Chinese researchers, published in Cell Discovery in 2024, independently corroborated these findings. They showed that 40Hz light flickering enhanced glymphatic flow through adenosine signaling, and that this effect occurred independently of sleep, though it complemented the glymphatic clearance that naturally occurs during sleep.

This is significant. The glymphatic system was only discovered in 2012, and our understanding of how to modulate it is still in its infancy. The finding that something as simple as rhythmic sensory stimulation can enhance the brain's built-in waste clearance system represents a fundamental shift in how we think about brain maintenance.

Key Research:

• Murdock et al., Multisensory Gamma Stimulation Promotes Glymphatic Clearance of Amyloid (Nature, 2024)
• Sun et al., 40Hz Light Flickering Facilitates the Glymphatic Flow via Adenosine Signaling in Mice (Cell Discovery, 2024)
• How Sensory Gamma Rhythm Stimulation Clears Amyloid in Alzheimer's Mice (MIT News, 2024)

Three Modalities, One Frequency

What makes 40Hz research uniquely compelling is that the effects are not limited to a single sensory pathway. Researchers have demonstrated gamma entrainment through three distinct modalities, and each one activates different but complementary brain regions.

Light (Visual Gamma Entrainment)

Stroboscopic light flickering at 40Hz was the first modality studied in the GENUS framework. Visual stimulation at this frequency entrains neural activity in the visual cortex and, critically, in deeper brain structures including the hippocampus, the brain's memory center.

A 2025 study using intracranial EEG recordings in human patients confirmed that 40Hz visual stimulation successfully entrains neural activity beyond early visual areas, reaching the hippocampus, temporal lobes, and frontal cortex. The researchers also found that coupling stimulation with a simple visual attention task enhanced the response and altered information flow between frontal regions and the hippocampus.

Another 2025 study demonstrated that 40Hz visual stimulation during sleep evoked neuronal gamma activity during both NREM and REM stages without degrading sleep quality, opening the door to overnight stimulation protocols.

Key Research:

• Mlinarič et al., Visual Gamma Stimulation Induces 40Hz Neural Oscillations in the Human Hippocampus (Communications Biology, 2025)
• 40Hz Visual Stimulation During Sleep Evokes Neuronal Gamma Activity in NREM and REM Stages (SLEEP, 2025)

Sound (Auditory Gamma Entrainment)

Auditory 40Hz stimulation, delivered through clicking or pulsed sound, entrains gamma activity through auditory processing pathways. MIT's research demonstrated that 40Hz auditory stimulation alone reduced amyloid deposits in the auditory cortex and hippocampus, decreased tau phosphorylation, and improved cognitive performance in mouse models.

When combined with visual stimulation, the effects were amplified. Combined audiovisual stimulation at 40Hz, but not either modality alone, produced microglial-clustering responses and decreased amyloid in the medial prefrontal cortex. Whole-brain analysis revealed widespread reduction of amyloid plaques throughout the neocortex after multi-sensory GENUS.

An exploratory pilot study on binaural beat entrainment at 40Hz in healthy humans showed a trend toward improved cognitive test scores and mood after four weeks of sessions, though the results reached only weak statistical significance (p=0.076) with just three participants per frequency group. The study is preliminary but directionally consistent with the broader body of 40Hz research.

Key Research:

• Martorell et al., Multi-Sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition (Cell, 2019)
• Gamma Entrainment Frequency Affects Mood, Memory, and Cognition (PMC, 2020)

Vibration (Tactile Gamma Entrainment)

In 2023, MIT extended the GENUS framework to a third modality: whole-body vibrotactile stimulation at 40Hz. This is where things get especially relevant for vibroacoustic therapy.

Alzheimer's model mice exposed to 40Hz vibration for one hour per day over several weeks showed increased neural activity in the primary somatosensory cortex and primary motor cortex. They also showed significant reductions in phosphorylated tau, preserved neuron populations, maintained synaptic connections, and reduced DNA damage. Critically, the vibration-treated mice also showed improved motor function, a benefit that had not been demonstrated with light or sound alone.

A 2024 cellular study (in vitro) further confirmed that 40Hz vibrotactile stimulation improved cell viability in amyloid-exposed neurons, reduced toxic calcium buildup, activated autophagy (cellular self-cleaning), reduced tau hyperphosphorylation, and demonstrated anti-neuroinflammatory effects in microglia.

A March 2025 preprint (not yet peer-reviewed) comparing vibrotactile stimulation to audiovisual stimulation in healthy human participants found that a vibrotactile glove could evoke 40Hz EEG responses in central, frontal, and occipital cortices. Notably, participants preferred the vibrotactile stimulation over audiovisual stimulation, reporting it as more comfortable and sustainable for long-term use.

Key Research:

• Suk et al., Vibrotactile Stimulation at Gamma Frequency Mitigates Pathology Related to Neurodegeneration and Improves Motor Function (Frontiers in Aging Neuroscience, 2023)
• Shin et al., Vibrotactile Stimulation at 40Hz Inhibits Amyloid-Beta-Induced Changes in Neurons, Pericytes, and Microglia (Brain Research Bulletin, 2025)
• Comparing Vibrotactile Stimulation to Combined Visual and Auditory Stimulation for 40Hz Gamma Entrainment (bioRxiv, 2025)
• 40Hz Vibrations Reduce Alzheimer's Pathology, Symptoms in Mouse Models (MIT News, 2023)

40Hz and Chronic Pain: A New Central Pathway

In March 2026, researchers published a study in Cell Research that opens an entirely new therapeutic dimension for 40Hz stimulation: chronic pain relief.

The team, led by Jiang-Fan Chen and Yi Zhang (the same group behind the glymphatic adenosine research cited earlier), discovered in a mouse study that 40Hz flickering light significantly alleviated both inflammatory and neuropathic chronic pain. The analgesic effect was frequency-specific: 40Hz produced the strongest and most reliable results. 20Hz and steady light failed to provide meaningful pain relief. 80Hz produced weaker, inconsistent effects. The pain relief persisted for more than six hours after stimulation ended.

What makes this study remarkable is the circuit they identified. Using monosynaptic tracing, the researchers mapped a direct retina-to-central amygdala (CeA) pathway, a neural connection from retinal ganglion cells straight to one of the brain's key pain-processing and emotional centers. This pathway had not been previously described. They demonstrated that it was both necessary and sufficient for the analgesic effect: activating it reproduced the pain relief, and blocking it abolished it.

The molecular mechanism? Adenosine signaling, once again. 40Hz light flickering increased extracellular adenosine levels in the amygdala. Blocking adenosine transport eliminated the analgesic effect. Direct adenosine infusion into the amygdala reproduced it. The effect required A2A adenosine receptor signaling, and when they tested the protocol in A2A receptor knockout mice, the pain relief disappeared entirely.

Two additional findings stand out. First, the target neurons in the amygdala were predominantly enkephalinergic, meaning the 40Hz stimulation activated the brain's own endogenous opioid-releasing cells and increased enkephalin release. Second, the researchers showed that 40Hz light could destabilize and erase "pain memory" in the amygdala, essentially disrupting the central sensitization that keeps chronic pain going even after the original injury has healed. This mirrors memory reconsolidation processes and positions the amygdala as a target for pain memory erasure.

Key Research:

• Chen et al., 40Hz Light Flickering Alleviates Chronic Pain via Adenosine Signaling in the Retina-Amygdala Pathway (Cell Research, 2026)
• Zhou et al., 40Hz Light Flickering Promotes Sleep Through Cortical Adenosine Signaling (Cell Research, 2024)
• Sun et al., 40Hz Light Flickering Facilitates the Glymphatic Flow via Adenosine Signaling in Mice (Cell Discovery, 2024)

The Body Benefits: 40Hz Vibration Beyond the Brain

The neurological research above has dominated the 40Hz conversation, but vibration at this frequency does not stop at the skull. The body responds to mechanical vibration through pathways that are well documented and clinically relevant in their own right.

Parkinson's Motor Symptoms: A Vibroacoustic Study

The most directly relevant study for vibroacoustic therapy comes from a 2020 double-blinded, randomized controlled trial (the gold standard study design) at Wilfrid Laurier University. Researchers delivered 40Hz vibration to Parkinson's disease patients using a physioacoustic chair, a device that transmits low-frequency sound waves through speakers embedded in the seating surface. This is essentially the same delivery mechanism as a vibroacoustic therapy bed: audio-frequency vibration coupled directly to the body through transducers, not a mechanically shaking platform.

After 12 weeks of treatment, the group receiving 40Hz physioacoustic vibration showed significant improvements in tremor, rigidity, bradykinesia (slowness of movement), and postural stability, as measured by the Unified Parkinson's Disease Rating Scale. The placebo group, which sat in an identical chair without vibration, showed no comparable improvement.

This is notable for two reasons. First, the delivery method is physioacoustic, making the findings directly applicable to vibroacoustic therapy equipment. Second, the improvements were measured 48 to 72 hours after the last treatment session, suggesting the benefits were not merely acute effects that disappeared once vibration stopped.

Pain, Muscle Recovery, and Tissue Health

Vibration therapy in the 20 to 50Hz range has one of the most robust evidence bases in the rehabilitation literature. A clinical commentary published in the International Journal of Sports Physical Therapy concluded that the research most strongly supports vibration's application for pain relief, improving tissue extensibility, increasing strength, and decreasing muscle soreness.

At 40Hz specifically, a study by Broadbent and colleagues found that vibration applied at 40Hz following intense exercise reduced delayed onset muscle soreness at 24, 96, and 120 hours compared to no treatment. The effect was measurable both subjectively (participants reported less pain) and objectively (reduced biomarkers of inflammation).

The pain relief mechanisms are well characterized at the peripheral level. Vibration activates Pacinian corpuscles and other mechanoreceptors, which transmit signals along large-diameter nerve fibers that can effectively "gate" pain signals traveling on smaller fibers. This is the gate control theory of pain in action, and it explains why vibration often provides immediate analgesic effects even before any tissue-level changes occur.

The 2026 Cell Research pain study discussed above adds a central dimension to this picture. While gate control explains the immediate, local analgesic effects of vibration, the discovery that 40Hz stimulation drives adenosine release and endogenous opioid activation in the brain's pain-processing circuitry suggests a parallel brain-level pathway. That study used light, not vibration, but the central amygdala receives convergent somatosensory input as well. If 40Hz vibration produces similar central effects, vibroacoustic therapy may address pain through both peripheral gating and central modulation simultaneously.

Bone Density and Musculoskeletal Health

Whole-body vibration in the 20 to 45Hz range has attracted significant attention for its effects on bone density. A meta-analysis of 30 randomized controlled trials found that vibration therapy improved bone mineral density, with particularly significant results in postmenopausal women. NASA originally explored vibration therapy as a means of preventing bone loss in astronauts during extended spaceflight, and the concept has since been studied extensively in populations at risk for osteoporosis.

The proposed mechanisms include direct stimulation of mechanosensors in bone cells (activating the Wnt/beta-catenin signaling pathway, which promotes bone formation), increased neuromuscular activation similar to weight-bearing exercise, and improved blood circulation to bone tissue. Research has also demonstrated that vibration can increase bone volume and trabecular thickness in the subchondral bone at frequencies including 40Hz.

Circulation and Inflammation

Vibration therapy promotes nitric oxide production, a key vasodilator, and enhances systemic blood flow and oxygen delivery to tissues. Animal studies have demonstrated increased vascular volume, blood flow, and angiogenesis (new blood vessel formation) in vibration-treated subjects.

On the inflammatory front, research has shown that whole-body vibration can significantly reduce circulating pro-inflammatory cytokines, including IL-6, IFN-gamma, and TNF-alpha, while increasing anti-inflammatory markers like IL-10. A Frontiers in Neurology review noted that vibration therapy also stimulates the release of irisin, a muscle-derived hormone linked to BDNF (brain-derived neurotrophic factor) secretion, creating a molecular bridge between the physical and neurological benefits of vibration.

Most of the musculoskeletal and circulatory research cited above used whole-body vibration platforms, where a person stands or sits on a mechanically oscillating surface. This is a different delivery mechanism than vibroacoustic therapy, which transmits vibration through audio transducers. The two share fundamental physics: both deliver rhythmic mechanical stimulation to body tissues at controlled frequencies. But the amplitude, direction, and distribution of forces differ. For a deeper comparison of these two approaches, see our article on vibroacoustic therapy beds vs. vibration plates.

The Parkinson's physioacoustic study is the strongest direct evidence for vibroacoustic delivery at 40Hz specifically, while the broader whole-body vibration literature provides context for understanding why vibration at these frequencies produces physiological effects, even though the delivery systems are not identical.

Key Research:

• Mosabbir et al., The Effects of Long-Term 40-Hz Physioacoustic Vibrations on Motor Impairments in Parkinson's Disease (Healthcare, 2020)
• Vibration Therapy: A Clinical Commentary (International Journal of Sports Physical Therapy, 2022)
• Haffner-Luntzer et al., Influence of Low-Magnitude High-Frequency Vibration on Bone Cells and Bone Regeneration (Frontiers in Bioengineering and Biotechnology, 2020)
• Systematic Review and Meta-Analyses on the Effects of Whole-Body Vibration on Bone Health (2022)
• The Effects of Whole-Body Vibration Therapy on Immune and Brain Functioning (Frontiers in Neurology, 2024)

From Lab to Living Room: Human Clinical Evidence

The research is no longer confined to animal models. Human clinical trials have produced encouraging results across multiple studies.

MIT's early-stage clinical trial (small, exploratory) enrolled 15 volunteers with mild Alzheimer's disease. After three months of daily one-hour sessions with combined 40Hz light and sound, the active group showed preservation of brain volume and trends toward improved cognitive scores compared to controls. A follow-up study tracked five volunteers who continued stimulation for approximately two years. The three participants with late-onset Alzheimer's showed cognitive scores that remained significantly higher than comparable patients in national databases, and two of the late-onset participants who provided plasma samples showed significantly decreased levels of tau proteins.

Cognito Therapeutics, an MIT spinoff, conducted the larger OVERTURE feasibility study (not powered for efficacy) with 76 participants. Their investigational device, Spectris AD (which has received FDA Breakthrough Device Designation), delivered EEG-verified 40Hz gamma oscillations through synchronized light and sound.

A separate clinical study found that 40Hz audiovisual stimulation improved nighttime sleep quality in Alzheimer's patients and stabilized daily functioning over a six-month treatment period.

As of mid-2025, Cognito completed enrollment of 670 participants in the HOPE pivotal study, a Phase III trial spanning 70 sites across the United States. Cognito has described it as the largest medical device trial ever focused solely on Alzheimer's disease. The study includes a 12-month treatment phase with a 12-month open-label extension.

Key Research:

• Chan et al., 40Hz Sensory Stimulation Induces Gamma Entrainment and Affects Brain Structure in Alzheimer's Patients (medRxiv, 2021)
• Hajos et al., Safety, Tolerability, and Efficacy Estimate of Evoked Gamma Oscillation in Mild to Moderate Alzheimer's Disease (Frontiers in Neurology, 2024)
• Study Suggests 40Hz Sensory Stimulation May Benefit Some Alzheimer's Patients for Years (MIT News, 2025)
• Cimenser et al., Sensory-Evoked 40Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients (Frontiers in Systems Neuroscience, 2021)
• Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study (BioSpace, 2025)

Beyond Alzheimer's: The Expanding Horizon

While Alzheimer's research has driven most of the clinical work to date, the PLOS Biology review from 2025 notes that emerging evidence suggests 40Hz gamma stimulation may benefit a range of other conditions, including Parkinson's disease, stroke recovery, anxiety, epilepsy, multiple sclerosis, and the cognitive side effects of chemotherapy. Separately, MIT's Tsai lab has been studying whether gamma stimulation can help with Down syndrome.

The 2026 chronic pain research described earlier in this article adds another significant entry to this list, with implications for the more than 20% of the global population living with chronic pain and facing the limitations of current pharmacological options.

A 2022 review of 40Hz audiovisual stimulation applications noted preliminary efficacy in treating cognitive dysfunction, mood disorders, and sleep impairment. Research into applications for language and motor rehabilitation is ongoing.

Key Research:

• Audiovisual Gamma Stimulation for the Treatment of Neurodegeneration (Journal of Internal Medicine, 2024)
• Gamma Oscillations and Application of 40Hz Audiovisual Stimulation to Improve Brain Function (PubMed, 2022)
• Zhao et al., Light-Based 40Hz Sensory Therapy for Brain Disorders: Physiological Basis, Therapeutic Mechanisms, and Future Prospects (Frontiers in Medicine, 2026)

What This Means for Vibroacoustic Therapy

The 40Hz vibrotactile research from MIT used a remarkably simple setup: speakers playing a 40Hz tone underneath mouse cages, creating whole-body vibration. The mice who received tactile vibration (on top of the sound everyone heard) showed the neuroprotective benefits. The vibration was the variable that made the difference.

Vibroacoustic therapy, the practice of delivering low-frequency sound through transducers in direct contact with the body, operates on the same fundamental delivery principle: controlled, rhythmic mechanical stimulation at specific frequencies coupled directly to body tissue. When you lie on a vibroacoustic therapy bed and feel sound move through your body, your somatosensory system is receiving rhythmic stimulation at the frequencies being played. The transducers convert audio signal into physical vibration that couples directly with your tissue, bone, and nervous system.

To be clear: we are not treating Alzheimer's disease, chronic pain, or any other neurological condition. But the science is telling us something important about the relationship between rhythmic sensory stimulation and brain health, and that science aligns with the mechanisms that vibroacoustic therapy and stroboscopic light technology engage.

The Coherence Principle

At Zenthesia, we talk a lot about coherence. It is the idea that the body and brain function best when their rhythmic systems are synchronized and operating in harmony, not forcefully optimized toward some arbitrary target.

The 40Hz gamma research supports this perspective beautifully. The mechanism is not about overpowering the brain with stimulation. It is about entrainment: providing a clean, consistent rhythmic signal that the brain's own neural networks can synchronize with. When that synchronization occurs, the downstream effects (glymphatic clearance, reduced inflammation, preserved synaptic connections, adenosine-mediated pain modulation) emerge naturally.

The published studies use precisely calibrated stimulation for a reason. The 2026 pain study reinforced this point directly: analgesic effects were both frequency-dependent and intensity-dependent, with 40Hz at sufficient intensity producing the strongest results and lower intensities falling short of statistical significance. While no study has directly compared high-fidelity versus low-fidelity delivery systems, the underlying physics of entrainment suggest that signal quality is not a trivial variable.

Where the Science Goes From Here

The next few years will be pivotal. Cognito Therapeutics' Phase III trial, with enrollment completed and a 12-month treatment phase underway, should yield results that will provide the largest dataset yet on whether 40Hz sensory stimulation can slow Alzheimer's progression in humans. MIT is recruiting participants aged 55 and older with normal memory but a family history of Alzheimer's to test whether early intervention could delay disease onset entirely.

The adenosine story may prove equally significant: if future research confirms this pathway generalizes across modalities, including vibrotactile stimulation, it would offer a mechanistic foundation for the effects that practitioners and users have reported from vibroacoustic therapy for decades.

Meanwhile, research groups worldwide are expanding the investigation into new modalities, new conditions, and new populations. The question is no longer "does 40Hz stimulation do anything?" The evidence that it does is now substantial. The questions are "how do we optimize it?" and "how far does it reach?"

For those of us who have been working with vibroacoustic therapy and consciousness exploration technologies for years, this moment feels like vindication. The tools we have been building, the experiences we have been facilitating, the coherence we have been pursuing: the science is catching up.

Zenthesia manufactures premium vibroacoustic therapy equipment, including the Sound Therapy Bed 2, and is an authorized dealer of the roXiva RX1 stroboscopic light device. We believe in transparency, technical excellence, and letting the science speak for itself. Nothing in this article constitutes medical advice or a claim to treat, cure, or prevent any disease. The research cited here is provided for educational purposes. Stroboscopic light stimulation may be inappropriate for individuals with photosensitive epilepsy or certain neurological conditions. If you are dealing with a neurological condition or chronic pain, please consult your healthcare provider before beginning any stimulation protocol. For a broader overview of vibroacoustic therapy research beyond 40Hz, see our research page.

References

1. Iaccarino et al. "Gamma Frequency Entrainment Attenuates Amyloid Load and Modifies Microglia." Nature 540, 230-235 (2016).
2. Martorell et al. "Multi-Sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition." Cell 177(2), 256-271 (2019).
3. Murdock et al. "Multisensory Gamma Stimulation Promotes Glymphatic Clearance of Amyloid." Nature 627, 149-156 (2024).
4. Sun et al. "40Hz Light Flickering Facilitates the Glymphatic Flow via Adenosine Signaling in Mice." Cell Discovery 10, 81 (2024).
5. Suk et al. "Vibrotactile Stimulation at Gamma Frequency Mitigates Pathology Related to Neurodegeneration and Improves Motor Function." Frontiers in Aging Neuroscience 15, 1129510 (2023).
6. Shin et al. "Vibrotactile Stimulation at 40Hz Inhibits Amyloid-Beta-Induced Changes in SH-SY5Y, BV2 Cells, and Pericytes." Brain Research Bulletin 220, 111138 (2025).
7. Hajos et al. "Safety, Tolerability, and Efficacy Estimate of Evoked Gamma Oscillation in Mild to Moderate Alzheimer's Disease." Frontiers in Neurology 15, 1343588 (2024).
8. Park & Tsai. "Innovations in Noninvasive Sensory Stimulation Treatments to Combat Alzheimer's Disease." PLOS Biology 23(2), e3003046 (2025).
9. Cimenser et al. "Sensory-Evoked 40Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients." Frontiers in Systems Neuroscience 15, 746859 (2021).
10. Blanco-Duque et al. "Audiovisual Gamma Stimulation for the Treatment of Neurodegeneration." Journal of Internal Medicine 295, 146-170 (2024).
11. Mlinarič et al. "Visual Gamma Stimulation Induces 40Hz Neural Oscillations in the Human Hippocampus and Alters Phase Synchrony and Lag." Communications Biology 8, 1301 (2025).
12. Hainke et al. "40Hz Visual Stimulation During Sleep Evokes Neuronal Gamma Activity in NREM and REM Stages." SLEEP 48(3), zsae299 (2025).
13. Mosabbir et al. "The Effects of Long-Term 40-Hz Physioacoustic Vibrations on Motor Impairments in Parkinson's Disease: A Double-Blinded Randomized Control Trial." Healthcare 8(2), 113 (2020).
14. Lupowitz. "Vibration Therapy: A Clinical Commentary." International Journal of Sports Physical Therapy 17(6), 984-987 (2022).
15. Haffner-Luntzer et al. "Influence of Low-Magnitude High-Frequency Vibration on Bone Cells and Bone Regeneration." Frontiers in Bioengineering and Biotechnology 8, 595139 (2020).
16. DadeMatthews et al. "Systematic Review and Meta-Analyses on the Effects of Whole-Body Vibration on Bone Health." Complementary Therapies in Medicine 65, 102811 (2022).
17. Sievert et al. "The Effects of Whole-Body Vibration Therapy on Immune and Brain Functioning: Current Insights in the Underlying Cellular and Molecular Mechanisms." Frontiers in Neurology 15, 1422152 (2024).
18. Chen et al. "40Hz Light Flickering Alleviates Chronic Pain via Adenosine Signaling in the Retina-Amygdala Pathway." Cell Research (2026).
19. Zhou et al. "40Hz Light Flickering Promotes Sleep Through Cortical Adenosine Signaling." Cell Research 34, 214-231 (2024).
20. Zhao et al. "Light-Based 40Hz Sensory Therapy for Brain Disorders: Physiological Basis, Therapeutic Mechanisms, and Future Prospects." Frontiers in Medicine 13, 1730333 (2026).
21. Broadbent et al. "Vibration Therapy Reduces Plasma IL6 and Muscle Soreness After Downhill Running." British Journal of Sports Medicine 44(12), 888-894 (2010).